Compare Adaptive Biotechnologies Corp (ADPT) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Nokia Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.01 (market cap $4.04B), while Nokia Corp trades at $10.38 (market cap $53.00B). The key difference: Nokia Corp is far larger — about 13.1× Adaptive Biotechnologies Corp's market cap, and Nokia Corp pays a 1.73% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NOK | |
|---|---|---|
Market Cap | $4.04B | $53.00B |
Sector | Health | Technology |
52-Week High | $25.45 | $16.83 |
52-Week Low | $12.30 | $4.13 |
Enterprise Value | $4.10B | $50.95B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Nokia (NOK) trades at $10.375, up 13.76% today, reflecting strong momentum amid AI infrastructure demand. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, Q2 2026 earnings beat profit estimates, driven by AI and cloud growth, though revenue missed. Analyst sentiment is bullish with 60% buy ratings, while cash flow trends indicate volatility with a net outflow of $1.16B in 2025.
The outlook is cautiously optimistic, with AI-driven demand offsetting telecom challenges. Key opportunities include expanding AI networking and cloud infrastructure, but risks involve uneven telecom spending and competitive pressures. Investors should weigh strong analyst support against cash flow instability and margin pressures for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
